Description:Technical Field of the Invention
The invention belongs to the field of medical technology relates to extraction and application of natural drug components of Murraya koenigii. The present invention particularly relates to a composition and process for the preparation of Murraya koenigii leaf extract for treating hyperuricemia.
Background of the Invention
Hyperuricemia is a chronic metabolic disorder that occurs when there is too much uric acid in the body. Excessive uric acid resultant from abnormal purine metabolism, which can lead to elevated uric acid levels in the blood. Hyperuricemia is an important risk factor that leads to a variety of other diseases such as gout, hypertension and diabetes. The symptoms of Hyperuricemia occurred in the body when people's lifestyle and dietary structure changes. The preventive and treatment strategy for the prevention and treatment of hyperuricemia is either inhibiting uric acid formation to reduce serum uric acid levels and promoting uric acid excretion through the body. There are drugs available that may inhibit uric acid synthesis and that increase uric acid excretion. However, there may some side effects presents with the uric acid-lowering drugs such as toxic side effects or internal damage to the body organs. Therefore, there is an urgent need to develop new hypouricemic drugs to improve the conditions caused by the disease. Traditional herbal medicines have been shown to be vital in preventing human disease and have been used to treat uric acid and inflammation without severe side effects. Although various medicinal plants extract are evaluated for for treating hyperuricemia activity but still there is a need for plant-based gout treatment [Mahomoodally, M.F., Coodian, K., Hosenally, M., Zengin, G., Shariati, M.A., Abdalla, A.N., Alhazmi, H.A., Khuwaja, G., Mohan, S. and Khalid, A., 2024. Herbal remedies in the management of hyperuricemia and gout: A review of in vitro, in vivo and clinical evidences. Phytotherapy Research; Wang, S., Liu, W., Wei, B., Wang, A., Wang, Y., Wang, W., Gao, J., Jin, Y., Lu, H., Ka, Y. and Yue, Q., 2024. Traditional Herbal Medicine: Therapeutic Potential in Acute Gouty Arthritis. Journal of Ethnopharmacology, p.118182; Wang, H., Chu, Z., Ni, T., Chen, D., Dai, X., Jiang, W., Sunagawa, M. and Liu, Y., 2024. Effect and mechanism of aqueous extract of Chinese herbal prescription (TFK) in treating gout arthritis. Journal of Ethnopharmacology, 321, p.117527]. However, there is currently less literature is present for Murraya koenigii extract for the treatment of hyperuricemia. The Murraya koenigii extract for treating hyperuricemia in the present invention can inhibit uric acid synthesis and increase uric acid excretion at the same time. The Murraya koenigii extract may has a very good uric acid lowering effect; and it is a medicinal material that may be used as medicine and is safer and more reliable.
Objects of the Invention
The main object of the present invention is to provide a composition of Murraya koenigii leaves extract.
Another object of present invention is to provide a process for the preparation of Murraya koenigii extract.
Yet another object of present invention is to provide a process for the preparation of Murraya koenigii extract that solves the problems of low extraction efficiency, low purity and large loss of active ingredients by optimizing the preparation method of Murraya koenigii leaf extract.
Yet another object of the present invention is to provide Murraya koenigii leaves extract showing Hypouricemic activity.
Summary of the Invention
Accordingly, the present invention provides a composition of Murraya koenigii extract with Hypouricemic activity. In an embodiment of the present invention, the composition of Murraya koenigii extract with Hypouricemic activity, comprising: a) Murraya koenigii extract; and b) solvents; wherein the plant part used in Murraya koenigii extract is leaves of Murraya koenigii; wherein the solvents used are Petroleum ether, chloroform, ethanol and water; wherein the ethanolic extract of Murraya koenigii leaves show Hypouricemic activity in pyrazinamide induced hyperurecemia. The present invention provides a process for the preparation of Murraya koenigii extract. In an embodiment of the present invention, the process for the preparation of Murraya koenigii extract, comprising: a) collecting and ishing leaves of Murraya koenigii and thoroughly 2-3 times with running water and with distilled water; b) air-drying the washed leaves of Murraya koenigii of step a) under shade; c) crushing and powdering the dried leaves of Murraya koenigii of step b) and passing through sieve No 40; d) macerating separately the powdered leaves of step c) with 250 ml of solvents (Pet ether, chloroform, ethanol and water) in a tightly covered round bottom flask up to seven days period with intermittent shaking; e) filtering the extract after seven days using Whatman filter paper No A-1; f) obtaining the filtrates from organic solvents like petroleum ether, chloroform and ethanol and allowing to air dry; g) concentrating the aqueous extract in vacuum at 37ºC using a rotary vacuum evaporator and storing all dried extracts in a desiccator. In an embodiment of the present invention, the composition of Murraya koenigii extract, wherein the 350 gm of dried leaf powder of Murraya koenigii is extracted with 250 ml solvents. In an embodiment of the present invention, the composition of Murraya koenigii extract, wherein the Percentage Yield of extract with solvents Petroleum Ether, Chloroform, Ethanol and Aqueous are 3.9%, 3.1%, 6.3% and 7.7%. In an embodiment of the present invention, the composition of Murraya koenigii extract, wherein the alcoholic and aqueous extracts of Murraya koenigii leaves at 250 mg/ kg show Hypouricemic activity; wherein the ethanolic extract of Murraya koenigii leaves show maximum Hypouricemic activity. In an embodiment of the present invention, the composition of Murraya koenigii extract, wherein the acute toxicity studies for the prepared extracts are done in the dose range of 500, 1000, 2500 and 5000 mg/kg body weight. In an embodiment of the present invention, the composition of Murraya koenigii extract, wherein the extracts are given to rats by oral route at a dose level of 500, 1000 and 2500 mg/kg body weight, to groups of 4 animals; no death occurred within 24 h of dose of 500, 1500 mg/kg but at a dose of 2500 mg/kg 50% mortality is observed; ss dose is increased further up to 5000 mg/kg, at that dose all the animals are died showing 2500 mg/kg dose is considered as LD50. In an embodiment of the present invention, the composition of Murraya koenigii extract, wherein the screening of Hypouricemic activity of Murraya koenigii leaves extract is performed by the serum uric acid levels of experimental groups after treatment of different extracts of curry leaves of Murraya koenigii pet ether extract, Murraya koenigii chloroform extract, Murraya koenigii ethanolic extract and Murraya koenigii aqueous extract. In an embodiment of the present invention, the composition of Murraya koenigii extract, wherein the Pyrazinamide at 250 mg/kg b.wt is able to produce significant elevation of serum uric acid levels in one week and alcoholic and aqueous extracts are only having Hypouricemic activity at 250 mg/kg, The composition of Murraya koenigii extract, wherein the ethanolic extract of Murraya koenigii leaves produced maximum hypouricemic effect. The present invention is to provide a process for the preparation of Murraya koenigii extract that solves the problems of low extraction efficiency, low purity and large loss of active ingredients by optimizing the preparation method of Murraya koenigii leaf extract.
Brief Description of ings
In the drawings accompanying the specification, Figure 1 shows leaves of Murrya koenigii.
In the drawings accompanying the specification, Figure 2 shows induction of Hyperurecemia with different doses of Pyrazinamide.
In the drawings accompanying the specification, Figure 3 shows the effect of different extracts of Murraya koenigii leaves on serum uric acid levels at 150 and 250 mg /kg body wt.
Detailed description of the Invention
The present invention provides a composition of Murraya koenigii extract with Hypouricemic activity, comprising: a) Murraya koenigii extract; and b) solvents; wherein the plant part used in Murraya koenigii extract is leaves of Murraya koenigii; wherein the solvents used are Petroleum ether, chloroform, ethanol and water; wherein the ethanolic extract of Murraya koenigii leaves show Hypouricemic activity in pyrazinamide induced hyperurecemia. The present invention provides a process for the preparation of Murraya koenigii extract, comprising: a) collecting and ishing leaves of Murraya koenigii and thoroughly 2-3 times with running water and with distilled water; b) air-drying the washed leaves of Murraya koenigii of step a) under shade; c) crushing and powdering the dried leaves of Murraya koenigii of step b) and passing through sieve No 40; d) macerating separately the powdered leaves of step c) with 250 ml of solvents (Pet ether, chloroform, ethanol and water) in a tightly covered round bottom flask up to seven days period with intermittent shaking; e) filtering the extract after seven days using Whatman filter paper No A-1; f) obtaining the filtrates from organic solvents like petroleum ether, chloroform and ethanol and allowing to air dry; g) concentrating the aqueous extract in vacuum at 37ºC using a rotary vacuum evaporator and storing all dried extracts in a desiccator. The composition of Murraya koenigii extract, wherein the 350 gm of dried leaf powder of Murraya koenigii is extracted with 250 ml solvents. The composition of Murraya koenigii extract, wherein the Percentage Yield of extract with solvents Petroleum Ether, Chloroform, Ethanol and Aqueous are 3.9%, 3.1%, 6.3% and 7.7%. The composition of Murraya koenigii extract, wherein the alcoholic and aqueous extracts of Murraya koenigii leaves at 250 mg/ kg show Hypouricemic activity; wherein the ethanolic extract of Murraya koenigii leaves show maximum Hypouricemic activity. The composition of Murraya koenigii extract, wherein the acute toxicity studies for the prepared extracts are done in the dose range of 500, 1000, 2500 and 5000 mg/kg body weight. The composition of Murraya koenigii extract, wherein the extracts are given to rats by oral route at a dose level of 500, 1000 and 2500 mg/kg body weight, to groups of 4 animals; no death occurred within 24 h of dose of 500, 1500 mg/kg but at a dose of 2500 mg/kg 50% mortality is observed; ss dose is increased further up to 5000 mg/kg, at that dose all the animals are died showing 2500 mg/kg dose is considered as LD50. The composition of Murraya koenigii extract, wherein the screening of Hypouricemic activity of Murraya koenigii leaves extract is performed by the serum uric acid levels of experimental groups after treatment of different extracts of curry leaves of Murraya koenigii pet ether extract, Murraya koenigii chloroform extract, Murraya koenigii ethanolic extract and Murraya koenigii aqueous extract. The composition of Murraya koenigii extract, wherein the Pyrazinamide at 250 mg/kg b.wt is able to produce significant elevation of serum uric acid levels in one week and alcoholic and aqueous extracts are only having Hypouricemic activity at 250 mg/kg, The composition of Murraya koenigii extract, wherein the ethanolic extract of Murraya koenigii leaves produced maximum hypouricemic effect. The present invention is to provide a process for the preparation of Murraya koenigii extract that solves the problems of low extraction efficiency, low purity and large loss of active ingredients by optimizing the preparation method of Murraya koenigii leaf extract.
MATERIALS AND METHODS
The plant leaves are collected from the local area and identified the same for physical characteristics on morphology of Murraya koenigii. The collected plant leaves are washed thoroughly 2-3 times with running water and with distilled water. The leaves are air-dried under shade. The leaves are crushed to make possible fine powder.
Figure 1 shows leaves of Murrya koenigii.
Preparation of different extracts by cold maceration method
350 gm of dried leaf powder passed through sieve No 40 is macerated with 250 ml of solvent (Pet ether, chloroform, ethanol and water) in a tightly covered round bottom flask up to seven days period with intermittent shaking. After seven days the extracts are filtered by using filter paper (Whatman No A-1), marc is pressed. The filtrate obtained from organic solvents like pet ether, chloroform and ethanol is allowed to air dry. The aqueous extract is concentrated in vacuum at 37ºC using a rotary vacuum evaporator.
All dried extract are stored in a desiccator. The colour, appearance of physical nature of the extract are examined and recorded in Table 1.
Table 1:- The Percentage Yield of Petroleum Ether, Chloroform, Ethanol and Aqueous
S. No Solvent Nature of Extract Color %Yield
1 Pet.Ether (40-60˚C) Semisolid Greenish black 3.9
2 Chloroform Semisolid Dark green 3.1
3 Ethanol Semisolid Green 6.3
4 Aqueous Semisolid Brown 7.7

Induction of hyperurecemia in Male Wistar rats
In the present study Pyrazinimde selected as an inducer of hyperurecemia. Pyrazinamde an anti TB drug, its chronic use or at high doses causes hyperurecemia. Its metabolite pyrazinoate serve as the exchanging anion from inside cells, thereby stimulating anion exchange and urate reabsorption.
Dose titration of Pyrazinamide in rats
Pyrazinamide at higher doses or upon its chronic use elevates serum uric acid. Its metabolite pyrazinoate serve as the exchanging anion from inside cells, thereby stimulating anion exchange and urate reabsorption.
Animals:
Male Wistar rats weighing, 125-150 gm are selected and divided into three groups. Each group having 3 animals. Rats are kept in poly propylene cages and fed on standard laboratory diet. The animals are exposed to 12 hours of darkness and light each.
Estimation of Initial Serum uric acid levels
The blood samples are collected from each rat through tail vein puncture, allowed centrifugation for 15 min; serum is separated and estimated its initial serum uric acid levels using Uric acid kit.
Preparation of different doses of pyrazinamide
Pyrazinamide is soluble in cold water; its water solubility is 15mg/ml. In this work dose titration of Pyrazinamide is done at different doses i.e.150 mg/kg, 200mg/ kg and 250 mg/kg body weight. According to animal body weight dose of pyrazinamide is calculated and prepared according to its solubility.
Experimental design
Group I-treated with Pyrazinamide at dose of 150 mg/kg b.wt
Group II –treated with Pyrazinamide at dose of 200 mg /kg b.wt
Group III- treated with Pyrazinamide at dose of 250 mg/kg b.wt
Administration of Pyrazinamide to rats
The prepared pyrazinamide solution, at different doses is administered by oral route to each rat using oral feeding tube. Like this manner the dose administration is done upto seven days to ten days. Pyrazinamide at its high doses or at chronic use inhibit or reduce the uric acid excretion and elevates the blood uric acid level Excess uric acid in the blood is going to accumulate at the space between the joints and causes inflammation.
Estimation of serum uric acid after one week
After one week of daily administration of pyrazinamide, the serum uric acid levels are estimated by collecting blood from tail vein of each rat.
RESULTS:
Acute toxicity testing of plant extract
The prepared plant extracts from different solvents are evaluated. The acute toxicity studies for the prepared extracts are done in the dose range of 500.1000, 2500 and 5000 mg/kg body weight.
Acute toxicity study is carried out according to OECD guidelines. The extracts are given to rats by oral route at a dose level of 500, 1000 and 2500 mg/kg body weight, to groups of 4 animals. No death occurred within 24 h of dose of 500, 1500 mg/kg but at a dose of 2500 mg/kg 50% mortality is observed. As dose is increased further up to 5000 mg/kg, at that dose all the animals are died. Hence 2500 mg/kg dose is considered as LD50.
The Initial serum uric acid levels of rats are found to be in the range of 3.5-4.5 mg/dl. After one week daily administration of Pyrazinamide at higher dose (250mg/kg) is significantly increases the blood uric acid level up to 10.5 -11.0 mg/ dl. At tenth day we have seen acute flares at the joints of fore limbs, especially in the morning time. This stage indicates the development of acute phase of gout. The significantly elevated serum uric acid levels are maintained up to 30 days of drug discontinuation.
Figure 2 shows induction of Hyperurecemia with different doses of Pyrazinamide.
Screening of Hypourecemic activity of Murraya koenigii leaves
The serum uric acid levels of experimental groups after treatment of different extracts of curry leaves and standard drug is shown in the following Tables.
MKPE: Murraya koenigii pet ether extract
MKCE: Murraya koenigii chloroform extract
MKEE: Murraya koenigii ethanolic extract
MAKE: Murraya koenigii aqueous extract
 
Table 2: Serum Uric acid Levels after treatment with Standard Drug (Allopurinol)
Animal No Initial serum uric acid in mg /dl Serum uric acid level in hyperuricemic rats in mg/dl Serum uric acid level in mg/dl after treatment of Allopurinol
1 4.0 10.5 3.8
2 4.2 10.8 4.0
3 4.0 10.4 4.0
4 4.0 10.2 4.2
5 3.7 9.8 4.2
6 3.9 10.0 4.0

 
Table 3: Serum Uric acid Levels after treatment with Murraya koenigii pet ether extract (MKPE)
S. No Initial Serum uric acid levels in mg//dl Serum uric acid level in hyperuricemic rats in mg/dl Serum uric acid level in mg/dl after treatment of MKPE 250 mg /kg
1 4.0 10.0 9.5
2 4.0 10.2 9.4
3 4.4 10.5 9.5
4 4.2 10.6 9.5
5 4.4 10.8 9.6
6 4.0 10.3 9.3

 
Table 4: Serum Uric acid Levels after treatment with Murraya koenigii chloroform extract (MKCE)
S. No Initial Serum uric acid levels in mg//dl Serum uric acid level in hyperuricemic rats in mg/dl Serum uric acid level in mg/dl after treatment of MKCE 250mg/kg
1 4.0 10.5 9.4
2 4.2 10.6 9.2
3 4.0 10.3 9.3
4 3.6 10.0 9..0
5 3.8 10.0 8.9
6 4.0 10.4 9.2

 
Table 5: Serum Uric acid Levels after treatment with Murraya koenigii ethanolic extract (MKEE)
S. No Initial Serum uric acid levels in mg//dl Serum uric acid level in hyperuricemic rats in mg/dl Serum uric acid level in mg/dl after treatment of MKEE 250 mg/kg
1 3.8 10.0 4.2
2 4.0 10.2 4.5
3 4.0 10.1 4.6
4 4.0 10.4 4.7
5 4.2 10.6 4.8
6 4.4 11.0 5.0
Table 6: Serum Uric acid Levels after treatment with Murraya koenigii aqueous extract (MAKE)
S. No Initial Serum uric acid levels in mg//dl Serum uric acid level in hyper uricemia rats in mg/dl Serum uric acid level in mg/dl after treatment of MAKE 250 mg/kg
1 4.0 10.2 6.8
2 4.0 10.4 7.0
3 4.2 10.8 7.2
4 3.7 10.0 6.5
5 3.5 9.8 6.5
6 3.9 10.2 6.9
The alcoholic and aqueous extracts of Murraya koenigii leaves at 250 mg/ kg have comparable Hypourecemic activity with that of standard drug Allopurinol. The ethanolic extract of Murraya koenigii leaves is shown maximum Hypourecemic activity and Pet ether extract of Murraya koenigii leaves has shown minimum hypo uricemia activity.
Figure 3 shows the effect of different extracts of Murraya koenigii leaves on serum uric acid levels at 150 and 250 mg /kg body wt.
CONCLUSION:
This study is revealing that Pyrazinamide at 250 mg/kg b.wt is able to produce significant elevation of serum uric acid levels in one week. Curry leaves are rich in alkaloids, phenolic compounds, steroids and glycosides. Alcoholic and aqueous extracts are only having Hypourecemic activity at 250 mg/kg, Ethanolic extract of curry leaves produced maximum Hypourecemic activity whereas the minimum effect is produced by Pet ether extract of curry leaves. Murraya koenigii leaves having Hypourecemic activity is due to presence of Carbazole alkaloids and Phenolics.
REFERENCES
1. Adebajo AC, Ayoola OF, Iwalewa EO, Akindahunsi AA, Omisore NO, Adewunmi CO and Adenowo TK: Anti-trichomonal, biochemical and toxicological activities of methanolic extract and some carbazole alkaloids isolated from the leaves of Murraya koenigii growing in Nigeria. Phyto medicine 2006; 13(4): 246.
2. Baek BR, Kim MK, Lee SE, Hwang YH, Lee HS. Isolation of xanthine oxidase inhibitors from Ginkgo biloba leaves-derived components. J Food Sci Nutr. 2002; 7:18–21.
3. Becker MA, Jolly M: Clinical gout and the pathogenesis of hyperuricemia. In Arthritis and Allied Conditions, 15th ed. Edited by Koopman WJ, Moreland LW. Philadelphia: Lippincott, Williams& Wilkins; 2005, 2303-2339.
4. Hawkins,Rahn DW. Gout& Hyperuricemia. In:Dipiro JT.Talbert R L.Pharmacotherapy a pathological approach 6th ed.Toronato:MC Graw-Hill:2005.
5. Ichida K, Hosoyamada M, Hisatome I, Enomoto A,Hikita M,Endou H, Hosoya T: Clinical and molecular analysis of patients with renal hypouricemia in Japan: influence of URAT1 gene on urinary urate excretion. J Am Soc Nephrol 2004; 15:164-173.
6. Kesari AN, Gupta RK and Watal G: Hypoglycemic effect of Murraya koenigii on normal and alloxan-diabetic rabbits. Journal of Ethnopharmacology 2005; 97(2): 247-251.
7. Kessler, R. H., K. Hierholzer, and R. S. Gurd.Localization of urate transport in the nephron of mongrel and Dalmatian dog kidney. Amer. J. Physiol 1959; 197, 601.
8. Nguyen MT, Awale S, Tezuka Y, Tran QL, Watanabe H, Kadota S. Xanthine oxidase inhibitory activity of Vietnamese medicinal plants. Biol Pharm Bull. 2004; 27:1414–21.
9. Nguyen MT, Awale S, Tezuka Y, Ueda JY, Tran QL, Kadota S. Xanthine oxidase inhibitors from the flowers of Chrysanthemum sinense. Planta Med. 2006; 72:46–51.
10. Nik Najib Nik A. Rahaman, Takahisa Furuta, Someikojima, Kikuchi Takane, Mustafa Ali Mohd, “ Anti malarial activity of extracts of Malaysian Medicinal Plants”, J. Ethnopharmacology, 1999; 64, 249.
11. Pande MS, Gupta SPBN and Pathak A: Hepatoprotective Activity of Murraya koenigii Linn Bark. Journal of Herbal Medicine and Toxicology 2009; 3(1).
12. Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruble A. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 2002; 47:356–360.
13. Prichard JB and Miller DS. Renal secretion of organic anions and cations. J Kidney Int 1996; 49:1649–54.
14. Roch-Ramel F, Diezi J: Renal transport of organic ions and uric acid. In Diseases of the Kidney, 6th ed. Edited by Schreier RW,Gottschalk CE. Boston: Little Brown 1996;231-249.
15. Terkeltaub RA. Clinical practice. Gout. N Engl J Med. 2003; 349:1647-55.
16. Wilking JE, Mathias JK, Das K, Nidhaya ISR and Sudhakar G: Comparative Hepatoprotective Activity of Leaf Extracts of Murraya koenigii from Indian Subtropics. Indian Journal of Natural Product 2006; 23: 13-17.
17. Zachariah SM, Muthumani P and Ramaseshu K: Phytochemistry and Antimicrobial screening of stem bark of Murraya koenigii (Linn) spreng.The Internet Journal of Pharmacology 2009; 6(2).
, Claims:We claim:
1. A composition of Murraya koenigii extract with Hypouricemic activity, comprising:
a) Murraya koenigii extract; and
b) solvents;
wherein the plant part used in Murraya koenigii extract is leaves of Murraya koenigii;
wherein the solvents used are Petroleum ether, chloroform, ethanol and water;
wherein the ethanolic extract of Murraya koenigii leaves show Hypouricemic activity in pyrazinamide induced hyperurecemia.
2. A process for the preparation of Murraya koenigii extract, comprising:
a) collecting and ishing leaves of Murraya koenigii and thoroughly 2-3 times with running water and with distilled water;
b) air-drying the washed leaves of Murraya koenigii of step a) under shade;
c) crushing and powdering the dried leaves of Murraya koenigii of step b) and passing through sieve No 40;
d) macerating separately the powdered leaves of step c) with 250 ml of solvents (Pet ether, chloroform, ethanol and water) in a tightly covered round bottom flask up to seven days period with intermittent shaking;
e) filtering the extract after seven days using Whatman filter paper No A-1;
f) obtaining the filtrates from organic solvents like petroleum ether, chloroform and ethanol and allowing to air dry;
g) concentrating the aqueous extract in vacuum at 37ºC using a rotary vacuum evaporator and storing all dried extracts in a desiccator.
3. The composition of Murraya koenigii extract as claimed in claim 1, wherein the present invention is to provide a process for the preparation of Murraya koenigii extract that solves the problems of low extraction efficiency, low purity and large loss of active ingredients by optimizing the preparation method of Murraya koenigii leaf extract; wherein 350 gm of dried leaf powder of Murraya koenigii is extracted with 250 ml solvents.
4. The composition of Murraya koenigii extract as claimed in claim 1, wherein the Percentage Yield of extract with solvents Petroleum Ether, Chloroform, Ethanol and Aqueous are 3.9%, 3.1%, 6.3% and 7.7%.
5. The composition of Murraya koenigii extract as claimed in claim 1, wherein the alcoholic and aqueous extracts of Murraya koenigii leaves at 250 mg/ kg show Hypouricemic activity; wherein the ethanolic extract of Murraya koenigii leaves show maximum Hypouricemic activity.
6. The composition of Murraya koenigii extract as claimed in claim 1, wherein the acute toxicity studies for the prepared extracts are done in the dose range of 500, 1000, 2500 and 5000 mg/kg body weight.
7. The composition of Murraya koenigii extract as claimed in claim 1, wherein the extracts are given to rats by oral route at a dose level of 500, 1000 and 2500 mg/kg body weight, to groups of 4 animals; no death occurred within 24 h of dose of 500, 1500 mg/kg but at a dose of 2500 mg/kg 50% mortality is observed; ss dose is increased further up to 5000 mg/kg, at that dose all the animals are died showing 2500 mg/kg dose is considered as LD50.
8. The composition of Murraya koenigii extract as claimed in claim 1, wherein the screening of Hypouricemic activity of Murraya koenigii leaves extract is performed by the serum uric acid levels of experimental groups after treatment of different extracts of curry leaves of Murraya koenigii pet ether extract, Murraya koenigii chloroform extract, Murraya koenigii ethanolic extract and Murraya koenigii aqueous extract.
9. The composition of Murraya koenigii extract as claimed in claim 1, wherein the Pyrazinamide at 250 mg/kg b.wt is able to produce significant elevation of serum uric acid levels in one week and alcoholic and aqueous extracts are only having Hypouricemic activity at 250 mg/kg,
10. The composition of Murraya koenigii extract as claimed in claim 1, wherein the ethanolic extract of Murraya koenigii leaves produced maximum hypouricemic effect.
Dated this 10th day of January, 2025